LIGAND PHARMACEUTICALS INC
LGNDZDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 23, 2026
15wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
lasofoxifene
Osteoporosis
Aplindore
Restless Legs Syndrome
Bexarotene
Sarcoma, Kaposi
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
Aplindore | Phase 2 | Restless Legs Syndrome | - | - |
Bexarotene | Phase 2 | Sarcoma, Kaposi | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LIGAND PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in LIGAND PHARMACEUTICALS INC's (LGNDZ) pipeline across Phase 3, Phase 2. Its lead program is lasofoxifene (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIGAND PHARMACEUTICALS INC's next FDA catalyst?→
LIGAND PHARMACEUTICALS INC's (LGNDZ) next tracked catalyst is a PDUFA expected November 23, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LGNDZ biotech catalysts?→
Add LGNDZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIGAND PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.